Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc
("Summit" or the "Company")

EXERCISE OF SHARE OPTIONS

Oxford, UK, 30 July 2015 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that, following an exercise of share options, application has been made to AIM for the admission of 5,700 new ordinary shares of 1.0p each (the "New Ordinary Shares").

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 61,290,740.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares, which will rank pari passu with the Company's existing ordinary shares in issue, is expected to occur on or around 4 August 2015.

- END -

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection.

For more information, please contact: